Management of hypertension in overweight and obese patients: A practical guide for clinicians
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The association between obesity and cardiovascular disease is well established, and up to 60% of overweight or obese patients have hypertension. Dietary interventions associated with modest weight loss are effective in controlling blood pressure and in reducing use of antihypertensive drug therapy in overweight and obese patients. However, long-term maintenance of weight loss is achieved only in a small proportion of patients. Orlistat and sibutramine may help to achieve and maintain weight loss but may not be sufficient to control blood pressure in overweight and obese hypertensive patients. Consequently, antihypertensive drug therapy is often necessary in addition to weight loss interventions. Few studies have investigated different antihypertensive drugs, specifically in overweight and obese patients with hypertension. Based on studies involving obese and nonobese patients, first-line treatment options include a diuretic alone or an angiotensin-converting enzyme (ACE) inhibitor alone. If monotherapy is inadequate for blood pressure control, combination therapy with diuretic and ACE inhibitor and/or combining either of these drugs with a calcium channel blocker are reasonable treatment options. Additional studies to further clarify the management of these patients are warranted.
- Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002, 288:1723–1727. CrossRef
- World Health Organization: Controlling the global obesity epidemic. http:/www.who.int/nut/obs.htm. Accessed March 2, 2005.
- Mokdad AH, Ford ES, Bowman BA, et al.: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76–79. CrossRef
- Must A, Spadano J, Coakley EH, et al.: The disease burden associated with overweight and obesity. JAMA 1999, 282:1523–1529. CrossRef
- Sharma AM, Engeli S, Pischon T: New developments in mechanisms of obesity-induced hypertension: role of adipose tissue. Curr Hypertens Rep 2001, 3:152–156.
- Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998, 158:1855–1867.
- Stevens VJ, Obarzanek E, Cook NR, et al.: Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. The Hypertension Prevention Research Group. Ann Intern Med 2001, 134:1–11. This trial clearly showed that patients who had lost weight and had maintained this weight reduction had a lower risk for developing hypertension. However, this goal is achieved by only few patients.
- National Institutes of Health, National Heart, Lung and Blood Institute, Obesity Education Initiative: Clinical Guidelines on the identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health; 1998.
- Rippe JM, Crossley S, Ringer R: Obesity as a chronic disease: modern medical and lifestyle management. J Am Diet Assoc 1998, 98(10 Suppl:2):S9-S15. CrossRef
- Serdula MK, Mokdad AH, Williamson DF, et al.: Prevalence of attempting weight loss and strategies for controlling weight. JAMA 1999, 282:1353–1358. CrossRef
- Dansinger ML, Gleason JA, Griffith JL, et al.: Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005, 293:43–53. CrossRef
- Foster GD, Wyatt HR, Hill JO, et al.: A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003, 348:2082–2090. CrossRef
- Stern L, Iqbal N, Seshadri P, et al.: The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med 2004, 140:778–785.
- Flechtner-Mors M, Ditschuneit HH, Johnson TD, et al.: Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obes Res 2000, 8:399–402. CrossRef
- Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. Finnish Diabetes Prevention Study Group. N Engl J Med 2001, 344:1343–1350. CrossRef
- Stamler R, Stamler J, Grimm R, et al.: Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial—the Hypertension Control Program. JAMA 1987, 257:1484–1491. CrossRef
- Whelton PK, Appel LJ, Espeland MA, et al.: Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998, 279:839–846. CrossRef
- Metz JA, Stern JS, Kris-Etherton P, et al.: A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med 2000, 160:2150–2158. CrossRef
- Yanovski SZ, Yanovski JA: Obesity. N Engl J Med 2002, 346:591–602. CrossRef
- Bakris G, Calhoun D, Egan B, et al.: Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. Orlistat and Resistant Hypertension Investigators. J Hypertens 2002, 20:2257–2267. CrossRef
- Lindgärde F: The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000, 248:245–254. CrossRef
- Sharma AM, Golay A: Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002, 20:1873–1878. CrossRef
- Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155–161. CrossRef
- McMahon FG, Fujioka K, Singh BN, et al.: Efficacy and safety of sibutramine in obese white and African-American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000, 160:2185–2191. CrossRef
- McMahon FG, Weinstein SP, Rowe E, et al.: Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. Sibutramine in Hypertensives Clinical Study Group. J Hum Hypertens 2002, 16:5–11. CrossRef
- Derosa G, Cicero AF, Murdolo G, et al.: Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005, 7:47–55. CrossRef
- Lloyd-Jones DM, Evans JC, Larson MG, et al.: Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000, 36:594–599.
- Bramlage P, Pittrow D, Wittchen HU, et al.: Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004, 17:904–910. CrossRef
- Lenfant C, Chobanian AV, Jones DW, Roccella EJ: Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 41:1178–1179. CrossRef
- Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611–616. CrossRef
- Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996, 275:1507–1513. CrossRef
- Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989, 321:868–873. CrossRef
- Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153. CrossRef
- Grassi G, Seravalle G, Dell’Oro R, et al.: Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003, 21:1761–1769. CrossRef
- Stein PP, Black HR: Drug treatment of hypertension in patients with diabetes mellitus. Diabetes Care 1991, 14:425–448. CrossRef
- Ueshiba H, Miyachi Y: Effect of doxazosin on insulin resistance in hypertensive patients with obesity. Horm Metab Res 2003, 35:532–536. CrossRef
- Pollare T, Lithell H, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988, 31:415–420. CrossRef
- CIBIS-2 study group: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9–13. CrossRef
- Ueshiba H, Miyachi Y: Effects of the long-acting calcium channel blockers, amlodipine, manidipine and clinidipine on steroid hormones and insulin resistance in hypertensive obese patients. Intern Med 2004, 43:561–565. CrossRef
- White WB, Elliott WJ, Johnson MF, Black HR: Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension. J Hum Hypertens 2001, 15:135–141. CrossRef
- Tarif N, Bakris GL: Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant 1997, 12:2244–2250. CrossRef
- ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997. This trial, which involved more than 35,000 hypertensive subjects with a mean follow up of 4.9 years, clearly showed that treatment with thiazide diuretics is at least as effective as treatment with lisinopril or amlodipine in the prevention of cardiovascular diseases. CrossRef
- Reaven GM, Clinkingbeard C, Jeppesen J, et al.: Comparison of the hemodynamic and metabolic effects of low dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 1995, 8(5Pt 1):461–466. CrossRef
- Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905–912. CrossRef
- Takahashi H, Nishikawa T, Mizutani T, Handa F: Oral clonidine premedication decreases energy expenditure in human volunteers. Can J Anaesth 1997, 44:268–272. CrossRef
- Management of hypertension in overweight and obese patients: A practical guide for clinicians
Current Hypertension Reports
Volume 7, Issue 5 , pp 330-336
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Industry Sectors